Clinical trials: Mild Neurocognitive Disorder
Alzheimer Disease, Mild Cognitive Impairment
Software Validation Study-Cognitive Status Indicator
The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- REMIND-V (NCT06809725)
- Testing
- SPARK Cognitive Status Indicator (software support data collected via EEG)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Alzheimer Disease, Mild Cognitive Impairment
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia.
- Trial name
- NCT06467539
- Testing
- DAOIB plus AO
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Technology
Therapeutic Effectiveness of PARO Companion Robot for Elderly With Mild Cognitive Impairment/Dementia in Elderly Residential Setting: A Quasi-experimental Study
The main trial is a 2-group quasi-experimental trial of comparing the outcome indicators between joining and not joining the 10-week personal assistive robot (PARO) training program in residents with dementia or mild cognitive…
- Trial name
- NCT05404802
- Testing
- Experimental group intervention, Control group intervention
- Where
- 2 sites in Hong Kong
- Volunteers
- 37 people
- Sponsor
- The University of Hong Kong
Cognitive Impairment, Mild Cognitive Impairment
Assessing Performance on Speech Tasks Via Crowdsourced Participants
The purpose of the study is to examine the properties of the Automatic Story Recall Test (ASRT) and its parallel variants, as well as letter fluency and category fluency cognitive tests.
- Trial name
- AMYWEB (NCT05298501)
- Testing
- No intervention/exposure
- Where
- United Kingdom
- Volunteers
- 1,034 people
- Sponsor
- Novoic Limited
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly
The primary objective is to examine the efficacy of 8-weeks of a locally developed brain-computer interface based system (BrainpalTM)intervention for improving attention and memory in normal elderly.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Cognitive Decline, Dementia
- Trial name
- 3ECog (NCT01661894)
- Testing
- BrainPalTM
- Where
- Singapore
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Duke-NUS Graduate Medical School
Dementia (Diagnosis), Mild Cognitive Impairment
Choose Myself (Before) Losing Myself
The purpose of this study is to see if an educational interactive booklet about how dementia progresses throughout a person's life can be a helpful tool for patients to think about future decisions that might need to be made…
- Conditions
- Dementia (Diagnosis), Mild Cognitive Impairment, Alzheimer's Disease Dementia, Alzheimer's Disease
- Trial name
- CYOA (NCT07846566)
- Testing
- CYOA booklet
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Mild Cognitive Impairment
The Relationship Between Metamemory and Memory in Old Age
The purpose of this research is to explore the relationship of metamemory and memory of elders and to evaluate the effectiveness of a metamemory cognitive intervention on elders with mild cognitive impairment and low memory…
- Trial name
- M&Mresearch (NCT02113345)
- Testing
- Metamemory Cognitive Intervention
- Where
- Hong Kong
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Alzheimer Disease, Mild Cognitive Impairment
Memory Enhancement Using Transcranial Alternating Current Stimulation
The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI)…
- Trial name
- Memento (NCT06202872)
- Testing
- Gamma (40 Hz) tACS at the precuneus region
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Amsterdam UMC, location VUmc
Alzheimer Disease, Dementia
ANNE Vital Sign System Remote Sleep Assessment
Sleep apnea is characterized by temporary pauses or stops to participant's breathing. Currently, sleep apnea is diagnosed using an in-lab sleep study, which involves spending a night in a sleep laboratory hooked up to wires on…
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Sleep Apnea
- Trial name
- NCT05669495
- Testing
- ANNE Vital Sign System
- Where
- Canada
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Parkinson&Amp;Amp;#39;s Disease (PD)
Mid-frontal Delta/Theta and Cognitive Control
Abstract Cognitive symptoms of Parkinson's disease (PD) include deficits in attention, working memory, and reasoning. These deficits affect up to 80% of PD patients and lead to mild cognitive impairment (PD-MCI) and dementia in…
- Trial name
- NCT06984757
- Testing
- Deep-brain Stimulation, Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
- Where
- United States
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Nandakumar Narayanan
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Mild Cognitive Impairment
ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)
Dementia is serious problem and around 700 000 people are affected in the UK alone. Currently there is no cure however early diagnosis and effective treatment offers hope for reducing the impact.
- Trial name
- ThinkingFit (NCT01603862)
- Testing
- ThinkingFit programme
- Where
- United Kingdom
- Volunteers
- 128 people
- Sponsor
- Dr Thomas Dannhauser
Mild Cognitive Impairment
A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment
The purpose of this study is to evaluate the psychometric properties of a Self-administered Memory Screening Test with Automated Reporting (SAMSTAR) adapted from the Rey Auditory Verbal Learning Test (RAVLT) in normal control…
- Trial name
- NCT02419183
- Testing
- SAMSTAR, RAVLT
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Hip Fractures, Mild Cognitive Impairment
Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment
Hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls.
- Trial name
- NCT04748354
- Testing
- Otago Exercise Program, Usual Care
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Mild to Moderate Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT03507790
- Testing
- CT1812
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Phase II Clinical Trial of Interleukin-2 in AD
Neuroinflammation is a significant component of Alzheimer disease (AD). Our group recently demonstrated that regulatory T cells (Tregs) have a compromised phenotype and reduced suppressive function in AD patients, skewing the…
- Trial name
- NCT06096090
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Mild Cognitive Impairment
Computer Games to Prevent Mild Cognitive Impairment and Dementia
The aim of the study is to show that regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/) can prevent mild cognitive impairment (MCI) and dementia.
- Trial name
- NCT02310620
- Testing
- Cognitive training
- Where
- Hungary
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Semmelweis University
Dementia, Alzheimer Disease
Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals
The goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during…
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
- Trial name
- NCT06017505
- Testing
- electronic self administered gerocognitive examination (eSAGE)
- Where
- United States
- Volunteers
- 1,486 people
- Sponsor
- Douglas Scharre